Skip to main content
Dr. Joseph S. Galati and Liver Specialists of Texas are pleased to announce the start of a new investigational study for patients with hepatitis C. 
As of September 2009, we will be having additional investigational studies for patients with hepatitis C. The studies are classified for patients based on any prior treatment for HCV.
Naive patients have never received any form of anti-viral therapy for hepatitis C. This would include Rebetron, Intron A, Ribavirin, PEG-Intron, Pegasys, or Infergen.
Other classes of patients will include those previously treated with any of the above drugs. Further, patients will be classified as either responder-relapsers, or non-responders.
Once we are able to screen your records, we can detwrmine if you could participate in any of the studies. There are several large companies sponsoring these studies, with a number of very exciting medications that will be used.

 The basic inclusion criteria for these study include:

  • male or female between 18-70 years old
  • HCV-RNA > 1000 IU/ml
  • HCV genotype 1
  • Diagnosed > 6 months before screening
  • No prior HCV treatment or
  • Failed at least 1 prior course of PEG-interferon /Ribavirin
If you feel you may be a candidate for this resaerch study, contact Herman Ortiz at 832-317-4665 for additional details and information. Patients accepted into the study will receive all treatment related care free of charge (labs, clinic visits, all study medication) as well as receive a financial reimbursement for each  clinic visit.
Additional hepatitis C studies are underway in addition to this study, targeting patients who have never been treated with any anti-viral therapy. You can contact Herman Ortiz and Liver Specialists of Texas for additional details.

Obesity and Fatty Liver Disease

Obesity, and all of its related complications, is more serious than most adults in America believe. More than one-third (34.9% or 78.6 million) of U.S. adults are obese. Obesity-related conditions include heart disease, stroke, type 2 diabetes, fatty liver disease, and certain types of cancer, are some of the leading causes of preventable death. We are seeing an increase in the number of young children and adolescents developing obesity, and all of the related complications.

The cost of obesity is staggering, with annual medical cost of obesity exceeding $147 billion in 2008 U.S. dollars. The medical costs for people who are obese were $1,429 higher than those of normal weight.

Dr. Galati and the Liver Specialists of Texas team are dedicated to evaluate, treat, and manage all aspects of obesity and non-alcoholic fatty liver disease (NAFLD and NASH), including the complication of cirrhosis and liver failure. Developing a customized plan of care for each patient they see is their objective.

Liver Transplant Resources

Dr. Galati has been involved in Liver Transplantation since 1989. As Medical Director for the Center for Liver Disease and Transplantation at Houston Methodist Hospital, Dr. Galati has cared for thousands of patients with advanced liver disease. In those with the most severe form of advanced liver disease and cirrhosis, liver transplantation is a life-saving surgery. For more information on liver transplantation, click here.

Indications for liver transplant include:

Online LIVER Second Opinion

  • 1

    From the comfort of your home, without the need to spend additional money on travel, lodging, and food, receive and expert second opinion from the expert physicians at Liver Specialists of Texas

  • 2

    There are five steps in the process of requesting a second opinion. We anticipate the steps will take you about 30-65 minutes to complete.

  • 3

    Have your medical records or those of your loved one on hand as you fill out the medical history questionnaire portion of the online process. The medical history questionnaire is detailed so having medical records to quickly reference will help make the process more efficient.

  • 4

    To start the process of an Online Liver Second Opinion, please fill out the initial contact form and fax back to our office. A representative from our office will call you for additional details.